Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and hansen's disease patients

Journal of Biochemical and Molecular Toxicology

Volumn 14, Issue 3, 2000, Pages 140-147

  Teo, S K ^a   Sabourin, P J ^b   O'Brien, K ^b   Kook, K A ^c   Thomas, S D ^a  

^a CELGENE CORPORATION   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c Salamandra LLC   (United States)

Author keywords

Cloned isozymes; Cytochrome P450; Human; Metabolism; Thalidomide

Indexed keywords

CYTOCHROME P450; ISOENZYME; RECOMBINANT PROTEIN; THALIDOMIDE;

ANIMAL; ARTICLE; ENZYMOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEPROSY; LIVER MICROSOME; METABOLISM; RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; LEPROSY; MICROSOMES, LIVER; RATS; RECOMBINANT PROTEINS; THALIDOMIDE;

EID: 0033630619     PISSN: 10956670     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0461(2000)14:3<140::AID-JBT3>3.0.CO;2-P     Document Type: Article

References (25)

1. Stirling DI. Thalidomide: a pharmaceutical enigma. Pharmaceut News 1996;3:7-20.
2. Tseng S, Pak G, Washenik K, Pomeranz M, Shupack J. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Derm 1996;35:969-979.
3. Moreira AL, Sampaio E, Zmuidzinas A, Frindt P, Smith K, and KaplanG. Thalidomide exerts its inhibitory action on TNF-α by enhancing mRNA degradation. J Exp Med 1993;177:1675-1680.
4. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 1994;91:4082-4085.
5. Hess C, Hunziker T, Kupfer A, Ludin H. Thalidomide-induced peripheral neuropathy. Neurology 1986;233:8389.
6. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, Arroyo-Figueroa H, Pasquetti A, Calva JJ. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 1996;10:1501-1507.
7. Kane SV, Ehrenpreis ED, Cohen LB, Hanauer SB, Cohen RD. Therapeutic efficacy of thalidomide for patients with refractory Crohn's disease (abstract). Gastroenterology 1999;116:A745. Abstract nr G3637.
8. Vasiliauskas EA, Kam LY, Abreu-Martin MT, Papadakis KA, Zeldis JB, Targan SR. An open-label, stepwise dose-escalating pilot study to evaluate the safety, tolerance, and efficacy of low-dose thalidomide in the treatment of chronically-active, steroid-dependent Crohn's disease (abstract). Gastroenterology 1999;116:A837. Abstract nr G3637.
9. Glass J, Gruber ML, Nirenberg A. Phase I/II study of carboplatin and thalidomide in recurrent glioblastoma multiforme (abstract). In: Perry M, editor. Program/Proceedings of the 34th meeting of the American Clinical Society of Oncologists, 1999 May 15-18. Atlanta: Acso, 1999. p 144a. Abstract nr 551.
10. Watanabe S, Pituskin E, Calder K, Neumann CM, Bruera E. Thalidomide in the symptomatic treatment of cachexia in patients (abstract). Program/Proceedings of the 34th meeting of the American Clinical Society of Oncologists, 1999 May 15-18. Atlanta: Acso, 1999. p 48a. Abstract nr 178.
11. Braun AG, Harding FA, Weinreb SL. Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. Toxicol Appl Pharmacol 1986;82:175-179.
12. Knoche B, Blaschke G. Stereoselectivity of the in vitro metabolism of thalidomide. Chirality 1994;6:221-224.
13. Tsambaos D, Bolsen K, Georgiou S, Monastirli A, Goerz G. Effects of oral thalidomide on rat liver and skin microsomal P450 isozyme activities and on urinary porphyrin excretion: interaction with oral hexachlorobenzene. Archiv Derm Res 1994;286:347-349H.
14. Schumacher H, Smith R, Williams R. The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Brit J Pharmacol 1965;25:338-351.
15. Schumacher H, Smith R, Williams R. The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Brit J Pharmacol 1965;25:324-337.
16. Schumacher H, Blake D, Gillette G. Disposition of thalidomide in rabbits and rats. J Pharm Exp Ther 1968;160:201-211.
17. Schumacher H, Wilson J, Terapane J, Rosedale S. Thalidomide: disposition in rhesus monkey and studies of its hydrolysis in tissues of this and other species. J Pharm Exp Ther 1970;173:265-269.
18. Guengerich FP. Inhibition of oral contraceptive steroid-metabolizing enzymes by steroids and drugs. Am J Obs Gyn 1990;163:2159-2163.
19. D'Arcy PF. Drug interactions with oral contraceptives. Drug Intell Clin Pharm 1986;20:353-362.
20. Faigle JW, Keberle H, Schmid K. The metabolic fate of thalidomide. Experientia 1962;15:389-397.
21. Gordon GB, Spielberg SP, Blake DA, Balasubramanian V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc Natl Acad Sci 1981,78:2545-2548.
22. Eriksson T, Bjorkman S, Roth B, Bjork H, Hoglund P. Hydroxylated metabolites of thalidomide: formation in vitro and in vivo in man. J Pharm Pharmacol 1998;50:1409-1416.
23. Reist M. Carrupt P-A, Francotte E, Testa B. Chiral inversion and hydrolysis of thalidomide mechanisms and catalysis by basis and serum albumin and chiral stability of teratogenic metabolites. Chem Res Toxicol 1998; 11:1521-1528.
24. Eriksson T, Bjorkman S, Roth B, Fyge A, Hoglund P. Stereospecific determination, chiral inversion in vitro, and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 1995;7:44-52.
25. Schroder J, Mattiesen T. Experimental thalidomide neuropathy: the morphological correlate of reduced conduction velocity. Acta Neuropathol 1985;65:285-292.